Cytokine analysis
A convenience sample of 33 MedCan-1 participants consented to the MedCan-Inflam sub-study. One did not complete baseline and was not randomised, three did not complete day 14, and a further 9 did not complete day 28. Patient characteristics are shown in Supplementary Table Cytokine analysis did not identify any difference in trajectory of any cytokine between the placebo and CBD groups (Table Inflammatory cytokines over time(136,323.1 (108,398.4 to 166,673.8)(137,493.1 (110,978.7 to 169,384.7)(140,605.9 (121,820 to 175,522.4)(175,095.2 (118,536.3 to 223,986)(163,553.6 (142,096 to 212,624.1)(176,663.6 (155,722 to 187,847.3)(12,193.9 (7128.6 to 20,529.3)(15,394.9 (7297.4 to 28,238)(32,126.7 (5902.6 to 39,407)(10,035.3 (4378.5 to 17,282.8)(8530.7 (6814.3 to 29,895.5)(7737 (5738.7 to 29,305.8)(55,580.6 (37,865.1 to 73,716.5)(42,300 (29,117.9 to 59,592.4)(37,679.5 (25,352.3 to 78,253.3)(48,480.6 (25,618.1 to 64,939.1)(42,328.3 (29,512.2 to 58,443.5)(53,288.1 (40,546.2 to 79,296.8)(292.1 (148.1 to 383.4)(303.2 (156.6 to 353.6)(258. (152.5 to 397.8)(217.6 (109.1 to 504.5)(155.5 (136.2 to 460.9)(423.8 (145 to 634.8)(9111.8 (6718.2 to 10,048.3)(10,093.4 (6121.8 to 11,619.6)(11,039.9 (4520.7 to 12,769.4)(9362.2 (5682.8 to 11,506.4)(7524 (5123.7 to 12,623.9)(6675.6 (4483.3 to 12,420.5)(26.6 (19.7 to 30.4)(21.2 (19.2 to 27.8)(20.8 (16.6 to 27.1)(24.1 (13.8 to 30.7)(22.1 (16.9 to 28.2)(22.2 (19.7 to 31)(22.6 (16.8 to 27.7)(22 (19.2 to 27.2)(29 (25.7 to 30.6)(21.6 (16.6 to 31.4)(19.2 (17.4 to 30.6)(19.9 (18.3 to 27.8)(9.3 (6.6 to 10.4)(7.9 (6.4 to 9.7)(8.7 (7 to 9.7)(9 (5.8 to 10.7)(9.6 (4.9 to 12.1)(8.1 (7.1 to 12.7)(47.8 (29.5 to 65.4)(38.3 (28.3 to 49.8)(37.7 (34.9 to 63.5)(41.7 (28.2 to 106.2)(35.2 (32 to 101)(50.9 (35.3 to 84.3)(65.1 (59.6 to 71.9)(71.3 (61.1 to 78.3)(71.6 (64.3 to 81.4)(70 (67.6 to 75.5)(71.5 (60.4 to 84.9)(80.5 (65.1 to 87.8)(3328.8 (3002.6 to 3867.9)(3307.6 (2249 to 4240.7)(3024.9 (2275.4 to 4080.7)(4189.1 (3047.1 to 4961.8)(3576.2 (3164.3 to 5232.2)(4505.6 (2803.6 to 4728.4)(5438.9 (1826.9 to 14,954.8)(4631.7 (1970.3 to 13,070.9)(4561.5 (2023.5 to 12,149.6)(2740.6 (1757.2 to 9406)(3892.9 (2376 to 10,442)(10,117.7 (1878.8 to 11,996.6)(12,873.3 (8589 to 16,173.4)(18,793.8 (10,573.9 to 24,857.5)(16,306.1 (7750 to 23,430.6)(18,433.8 (12,856.8 to 31,762.3)(17,720.3 (16,010.4 to 31,268.5)(16,819.6 (15,853 to 20,537.9)(1356.5 (869.8 to 3199.4)(538 (314.6 to 1894.4)(1202.7 (552.3 to 3719.2)(934.9 (376.2 to 2774.4)(1015.6 (431.6 to 2567)(1178.6 (783.6 to 2348.2)(5544.3 (3602.5 to 11,841.2)(6352.8 (2892.4 to 7719.2)(5871.6 (2589.3 to 12,840.9)(7176.8 (3009.3 to 9435.1)(6784.1 (1485.9 to 9404.6)(7191.3 (2983.7 to 20,887.6)(6269.4 (3996.3 to 8285.9)(4797.4 (3525.2 to 10,980.4)(5768.3 (3207.7 to 8664.6)(3115.9 (2607.2 to 11,801.7)(4751.2 (2852.1 to 13,028.8)(3839.1 (2133.8 to 15,217.9)(659.5 (277.1 to 818.2)(507.2 (339.8 to 708)(565.2 (280.5 to 869.6)(417.5 (329.9 to 1084.9)(435.6 (302.1 to 820.9)(745.9 (376.4 to 1174.1)(204.7 (159.12 to 431.4)(170.2 (143.7 to 407.3)(203.9 (187.6 to 233.5)(212.2 (156.7 to 399.1)(222.1 (181.2 to 377.2)(336.8 (208.9 to 543.4)(27.1 (17.6 to 35.4)(26.1 (20 to 32.5)(27.6 (26.4 to 29.9)(27.4 (18.3 to 56.3)(33.1 (17.9 to 55)(32.7 (16 to 39.3)(146.7 (90.9 to 295.5)(97.7 (75.1 to 351.8)(111.7 (94.3 to 202.4)(201 (86.8 to 251.9)(144.3 (103.6 to 393.1)(165.3 (120.7 to 359.9)(22,410.6 (11,938.4 to 30,716.7)(13,007.2 (11,605.1 to 25,924.8)(13,668.5 (11,772.9 to 28,182.7)(14,461.5 (11,499.6 to 26,121.6)(15,392.9 (11,462.8 to 19,021.4)(18,528 (12,652.6 to 24,687.9)*†Normal distribution with identity linkLine graph for IFN-gamma from baseline to day 28 for the 32 participants in the MedCan-Inflam sub-study. Thick lines indicate the median IFN-gamma value and grey lines the values for each individual participant